183 related articles for article (PubMed ID: 15994737)
1. Olanzapine and haloperidol for residual symptoms.
de Haan L; van Beveren N
Am J Psychiatry; 2005 Jul; 162(7):1392-3; author reply 1393. PubMed ID: 15994737
[No Abstract] [Full Text] [Related]
2. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
Zipursky RB; Christensen BK; Daskalakis Z; Epstein I; Roy P; Furimsky I; Sanger T; Kapur S
Can J Psychiatry; 2005 Jul; 50(8):462-9. PubMed ID: 16127964
[TBL] [Abstract][Full Text] [Related]
3. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
[TBL] [Abstract][Full Text] [Related]
4. Atypical antipsychotics, tardive dyskinesia, and D(2) receptors.
Duggal HS; Mendhekar DN
Am J Psychiatry; 2006 Aug; 163(8):1449-50. PubMed ID: 16877664
[No Abstract] [Full Text] [Related]
5. Positive findings for negative symptoms of schizophrenia: no longer untreatable?
Stahl SM
Acta Psychiatr Scand; 2006 Nov; 114(5):301-2. PubMed ID: 17022789
[No Abstract] [Full Text] [Related]
6. Olanzapine vs haloperidol for treatment of schizophrenia.
de Haan L; van Beveren N
JAMA; 2004 Mar; 291(9):1065; author reply 1065-6. PubMed ID: 14996769
[No Abstract] [Full Text] [Related]
7. Olanzapine for primary negative symptoms.
Licht RW
Am J Psychiatry; 1998 Aug; 155(8):1133-4. PubMed ID: 9699711
[No Abstract] [Full Text] [Related]
8. Olanzapine on trial.
Mattes JA
Am J Psychiatry; 1998 Jan; 155(1):153; author reply 153-5. PubMed ID: 9433359
[No Abstract] [Full Text] [Related]
9. Olanzapine treatment of residual positive and negative symptoms.
Buchanan RW; Ball MP; Weiner E; Kirkpatrick B; Gold JM; McMahon RP; Carpenter WT
Am J Psychiatry; 2005 Jan; 162(1):124-9. PubMed ID: 15625210
[TBL] [Abstract][Full Text] [Related]
10. Methodological concerns in a trial of ziprasidone and olanzapine.
Carnahan RM; Perry PJ
Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
[No Abstract] [Full Text] [Related]
11. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.
Battaglia J; Houston JP; Ahl J; Meyers AL; Kaiser CJ
Clin Ther; 2005 Oct; 27(10):1612-8. PubMed ID: 16330297
[TBL] [Abstract][Full Text] [Related]
12. SPECT studies of D2 occupancy in low-dose haloperidol treatment.
Hirschowitz J; Hitzemann R; Vallabhajosula S
Am J Psychiatry; 1997 May; 154(5):715-6. PubMed ID: 9137141
[No Abstract] [Full Text] [Related]
13. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
Wright P; Birkett M; David SR; Meehan K; Ferchland I; Alaka KJ; Saunders JC; Krueger J; Bradley P; San L; Bernardo M; Reinstein M; Breier A
Am J Psychiatry; 2001 Jul; 158(7):1149-51. PubMed ID: 11431240
[TBL] [Abstract][Full Text] [Related]
14. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.
Paquet F; Soucy JP; Stip E; Lévesque M; Elie A; Bédard MA
J Neuropsychiatry Clin Neurosci; 2004; 16(1):47-56. PubMed ID: 14990759
[TBL] [Abstract][Full Text] [Related]
15. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites.
Skilbeck KJ; O'Reilly JN; Johnston GA; Hinton T
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):492-8. PubMed ID: 17976880
[TBL] [Abstract][Full Text] [Related]
17. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
18. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
[TBL] [Abstract][Full Text] [Related]
19. An importance of dose in antipsychotic combination therapy for schizophrenia.
Suzuki T
J Clin Psychopharmacol; 2011 Jun; 31(3):399; author reply 399-400. PubMed ID: 21532376
[No Abstract] [Full Text] [Related]
20. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Volavka J; Nolan KA; Kline L; Czobor P; Citrome L; Sheitman B; Lindenmayer JP; McEvoy J; Lieberman JA
Schizophr Res; 2005 Jul; 76(1):127-9. PubMed ID: 15927808
[No Abstract] [Full Text] [Related]
[Next] [New Search]
